Management of nonsexually acquired genital ulceration using oral and topical corticosteroids followed by doxycycline prophylaxis - 18/04/13
Abstract |
Background |
Data regarding the treatment of nonsexually acquired genital ulceration (NSAGU) are limited.
Objective |
We sought to provide evidence for the safety and efficacy of topical and systemic corticosteroids followed by doxycycline prophylaxis for acute and recurrent NSAGU.
Methods |
A retrospective chart review was conducted of patients with NSAGU treated in a private dermogynecology practice.
Results |
A total of 26 girls and women with NSAGU were identified and divided into 2 groups: group A = 17 patients with moderate to severe ulceration treated in the acute stage with oral corticosteroid; and group B = 9 patients with mild ulceration treated in the acute stage with topical corticosteroid. Patients in group A, with a mean age of 27.9 years (range, 11-62 years), were treated with oral prednisolone commencing with 15 to 50 mg per day depending on severity. Sixteen (94%) achieved rapid pain relief and complete healing of ulcers within 16 days. Eight (47%) commenced doxycycline prophylaxis. Women in group B, with a mean age of 42.5 years (range, 26-67 years) were treated with topical corticosteroids. Eight (89%) had a history of recurrent ulcers and 6 (66%) commenced doxycycline prophylaxis. Of all 14 patients on doxycycline prophylaxis, none reported any recurrences during a mean follow-up of 18.3 months. There were no adverse effects caused by prednisolone. One patient experienced mild photosensitivity from doxycycline but continued to take it.
Limitations |
This was a retrospective case series from a single private practice–based population.
Conclusion |
Topical or oral corticosteroids followed by prophylactic doxycycline can be effective in rapidly resolving acute flareups and preventing recurrences of NSAGU. All patients responded to therapy without treatment-limiting side effects.
Le texte complet de cet article est disponible en PDF.Key words : aphthous ulcer, corticosteroid, doxycycline, genital, vulvar
Plan
Funding sources: None. |
|
Conflicts of interest: None declared. |
Vol 68 - N° 5
P. 797-802 - mai 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?